In this week’s Trade To Black Podcast, Shadd Dales and Benjamin A. Smith take the mic with Anthony Varrell off on vacation. We focus on the state of the U.S. cannabis and psychedelic investing environments as we enter into 2022. Our special guest in Mindset Pharma (CNSX: MSET) (OTCMKTS: MSSTF) CEO James Lanthier, whose company has risen 46.55% since December 17, despite the continuous decline in the Horizons Psychedelic Stock Index ETF.
Trade To Black Podcast Episode 17 CliffsNotes…
@2:05 CNBC release their key narratives for 2022. We discuss whether SAFE Banking has another shot of breaking through next year once Chuck Schumer pushes his Cannabis Administration and Opportunity Act (CAOA) gambit.
@3:30 Rumors are that Senator Corey Booker could be introducing a federal expungement Bill in January. Will that help MSOS and component stocks, even if there’s no direct benefit to the industry top line?
@4:40 Do you get into MSOs now or wait on the sidelines for now? Benjamin A. Smith weighs the pros and cons of the market right now.
@5:44 We discuss one of TDR’s top cannabis plays in 2022—AdvisorShares Pure US Cannabis ETF (MSOS)—and why it was included on our list.
@6:58 The opening weeks of 2022 could be an important one for cannabis stocks, as it will be an opportune time for tax loss sellers to re-enter the market ahead of an expected regulatory push. We discuss.
@9:49 If MSOS does indeed test all-time lows in Q1 2022, could this be a generational opportunity for investors? Prices are compelling on a long term basis now, and Shadd thinks a federal regulatory breakthrough will happen.
@11:55 Do you think the days of the sector moving in unison are over?
@13:30 Institutional interest should rise in 2022 if Big Pharma enter the space via development partnerships
@15:30 Mindset Pharma James Lanthier joins TDR as this week’s special guest.
To view our previous Trade To Black Podcast 16, click here.